Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Letter by Madias regarding the article, "Repolarization alternans reveals vulnerability to human atrial fibrillation".
Madias JE.
Circulation. 2012 Jan 31;125(4):e320; author reply e321. No abstract available.
Related citations
Letter by Montone et al regarding article, "Atrial fibrillation: outpatient presentation and management".
Montone RA, Mollo R, Nerla R.
Circulation. 2012 Jan 31;125(4):e318; author reply e319. No abstract available.
Letter by Karam and Marijon regarding article, "Atrial fibrillation: outpatient presentation and management".
Karam N, Marijon E.
Circulation. 2012 Jan 31;125(4):e317; author reply e319. No abstract available.
Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?
Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, Heidenreich PA, Hammill S, Yancy C, Peterson ED; Get With the Guidelines Steering Committee and Hospitals.
Circulation. 2012 Mar 6;125(9):1094-101. doi: 10.1161/CIRCULATIONAHA.111.066605. Epub 2012 Jan 27.
Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study.
Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB, Heckbert SR, Siscovick DS, Mozaffarian D.
Circulation. 2012 Mar 6;125(9):1084-93. doi: 10.1161/CIRCULATIONAHA.111.062653. Epub 2012 Jan 26.
Error occurred: cannot get document summary
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Reiffel JA.
Circulation. 2012 Jan 24;125(3):e292; author reply e293-4. No abstract available.
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Reynolds S, Parra D, Rosenstein RS.
Circulation. 2012 Jan 24;125(3):e291; author reply e293-4. No abstract available.
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Govindarajan R, Salgado E.
Circulation. 2012 Jan 24;125(3):e290; author reply e293-4. No abstract available.
Antiarrhythmic drug therapy for atrial fibrillation.
Zimetbaum P.
Circulation. 2012 Jan 17;125(2):381-9. Review. No abstract available.
Letter by Van Laecke and Vanholder regarding article, "Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2".
Van Laecke S, Vanholder R.
Circulation. 2012 Jan 3;125(1):e236. No abstract available.
New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.
Ansell J.
Circulation. 2012 Jan 3;125(1):165-70; discussion 170. Review. No abstract available.
Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism.
Granger CB, Armaganijan LV.
Circulation. 2012 Jan 3;125(1):159-64; discussion 164. Review. No abstract available.
Risk of sudden death in Wolff-Parkinson-White syndrome: how high is the risk?
Obeyesekere M, Gula LJ, Skanes AC, Leong-Sit P, Klein GJ.
Circulation. 2012 Feb 7;125(5):659-60. Epub 2012 Jan 3. No abstract available.
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.
Circulation. 2012 Feb 7;125(5):669-76. Epub 2012 Jan 3.
Rate control in atrial fibrillation: targets, methods, resynchronization considerations.
Heist EK, Mansour M, Ruskin JN.
Circulation. 2011 Dec 13;124(24):2746-55. Review. No abstract available.
Connexins and atrial fibrillation: filling in the gaps.
Kato T, Iwasaki YK, Nattel S.
Circulation. 2012 Jan 17;125(2):203-6. Epub 2011 Dec 8. No abstract available.
Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation.
Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK.
Circulation. 2012 Jan 17;125(2):216-25. Epub 2011 Dec 8.
Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
Carlquist JF, Anderson JL.
Circulation. 2011 Dec 6;124(23):2554-9. Review. No abstract available.
Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.
Morrow JP, Katchman A, Son NH, Trent CM, Khan R, Shiomi T, Huang H, Amin V, Lader JM, Vasquez C, Morley GE, D'Armiento J, Homma S, Goldberg IJ, Marx SO.
Circulation. 2011 Dec 20;124(25):2812-21. Epub 2011 Nov 28.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on